Thrombosis in nephrotic syndrome

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 5, 2013, Pages 469-476

  Barbano, Biagio ^a   Gigante, Antonietta ^a   Amoroso, Antonio ^a   Cianci, Rosario ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

arterial thrombosis; deep vein thrombosis; nephrotic syndrome; proteinuria; pulmonary embolism; renal vein thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTITHROMBIN III; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CLOPIDOGREL; DIURETIC AGENT; FIBRINOGEN; GOLD; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; LIPOPROTEIN; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHOSPHOLIPID ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; STEROID; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR; WARFARIN;

ABDOMINAL SURGERY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CENTRAL VENOUS CATHETER; COMORBIDITY; CONGENITAL NEPHROTIC SYNDROME; DISEASE COURSE; DRUG USE; EDEMA; GENETIC PREDISPOSITION; GLOMERULOPATHY; GLOMERULUS CAPILLARY; GYNECOLOGIC SURGERY; HEART FAILURE; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; HYPOALBUMINEMIA; IATROGENIC DISEASE; IMMOBILIZATION; INTERSTITIAL NEPHRITIS; KIDNEY VEIN; KIDNEY VEIN THROMBOSIS; LIPOPROTEIN BLOOD LEVEL; LUNG EMBOLISM; MEMBRANOUS GLOMERULONEPHRITIS; MOLECULAR MECHANICS; NEPHROTIC SYNDROME; OBESITY; ORTHOPEDIC SURGERY; PATHOPHYSIOLOGY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEINURIA; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

HUMANS; KIDNEY GLOMERULUS; NEPHROTIC SYNDROME; RISK FACTORS; THROMBOPHILIA; THROMBOSIS;

EID: 84879116814     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1343887     Document Type: Article

References (87)

1. Nachman P. H., Jennette J. C., Falk R. J. Primary glomerular disease. In: Brenner B. M., ed. Brenner and Rector's The Kidney. 8th ed. Philadelphia, PA Saunders: 2007; 987 1042
2. Rostoker G., Behar A., Lagrue G. Vascular hyperpermeability in nephrotic edema. Nephron: 2000; 85 3 194 200
3. Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism. Br J Clin Pharmacol: 1999; 47 2 203 210
4. Galesic K., Ljubanovic D., Bulimbasic S., Racic I. Minimal change disease and acute tubular necrosis caused by diclofenac. Nephrology (Carlton): 2008; 13 1 87 88
5. Habib G. S., Saliba W., Nashashibi M., Armali Z. Penicillamine and nephrotic syndrome. Eur J Intern Med: 2006; 17 5 343 348
6. Perazella M. A., Markowitz G. S. Bisphosphonate nephrotoxicity. Kidney Int: 2008; 74 11 1385 1393
7. Barri Y. M., Munshi N. C., Sukumalchantra S., et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int: 2004; 65 2 634 641
8. Sakarcan A., Thomas D. B., O'Reilly K. P., Richards R. W. Lithium-induced nephrotic syndrome in a young pediatric patient. Pediatr Nephrol: 2002; 17 4 290 292
9. Kumasaka R., Nakamura N., Shirato K., et al. Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis. Clin Exp Nephrol: 2006; 10 3 222 225
10. Zhu X., Wu S., Dahut W. L., Parikh C. R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis: 2007; 49 2 186 193
11. George B. A., Zhou X. J., Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis: 2007; 49 2 e23 e29
12. Ponticelli C., Glassock Richard J. Treatment of Primary Glomerulonephritis. 2nd ed. New York, NY Oxford University Press: 2009; 21 26
13. Anderson S., Komers R., Brenner B. M. Renal and systemic manifestations of glomerular disease. In: Brenner and Rector's The Kidney. 8th ed. Philadelphia, PA Saunders: 2007; 821 823
14. Mikhailidis D. P., Ganotakis E. S. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets: 1996; 7 3 125 137
15. Remuzzi G., Mecca G., Marchesi D., et al. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res: 1979; 16 3-4 345 354
16. Eddy A. A., Symons J. M. Nephrotic syndrome in childhood. Lancet: 2003; 362 9384 629 639
17. Charlesworth J. A., Gracey D. M., Pussell B. A. Adult nephrotic syndrome: non-specific strategies for treatment. Nephrology (Carlton): 2008; 13 1 45 50
18. Citak A., Emre S., Sâirin A., Bilge I., Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol: 2000; 14 2 138 142
19. Cherng S. C., Huang W. S., Wang Y. F., Yang S. P., Lin Y. F. The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism. Clin Nucl Med: 2000; 25 3 167 172
20. Ozkayin N., Mir S., Kavakli K. Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity. Int Urol Nephrol: 2004; 36 4 599 603
21. Kerlin B. A., Ayoob R., Smoyer W. E. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol: 2012; 7 3 513 520
22. Vigano-D'Angelo S., D'Angelo A., Kaufman C. E. Jr, Sholer C., Esmon C. T., Comp P. C. Protein S deficiency occurs in the nephrotic syndrome. Ann Intern Med: 1987; 107 1 42 47
23. Al-Mugeiren M. M., Abdel Gader A. G., Al-Rasheed S. A., Al-Salloum A. A. Tissue factor pathway inhibitor in childhood nephrotic syndrome. Pediatr Nephrol: 2006; 21 6 771 777
24. Castellino P., Cataliotti A. Changes of protein kinetics in nephrotic patients. Curr Opin Clin Nutr Metab Care: 2002; 5 1 51 54
25. Bellomo R., Atkins R. C. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron: 1993; 63 3 249 254
26. Jensen H., Rossing N., Andersen S. B., Jarnum S. Albumin metabolism in the nephrotic syndrome in adults. Clin Sci: 1967; 33 3 445 457
27. Yssing M., Jensen H., Jarnum S. Albumin metabolism and gastrointestinal protein loss in children with nephrotic syndrome. Acta Paediatr Scand: 1969; 58 2 109 115
28. de Sain-van der Velden M. G., Kaysen G. A., de Meer K., et al. Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: measurements with stable isotopes. Kidney Int: 1998; 53 1 181 188
29. Kakafika A. I., Liberopoulos E. N., Mikhailidis D. P. Fibrinogen: a predictor of vascular disease. Curr Pharm Des: 2007; 13 16 1647 1659
30. Milionis H. J., Liberopoulos E., Goudevenos J., Bairaktari E. T., Seferiadis K., Elisaf M. S. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol: 2005; 99 2 269 275
31. Levenson J., Giral P., Megnien J. L., Gariepy J., Plainfosse M. C., Simon A. Fibrinogen and its relations to subclinical extracoronary and coronary atherosclerosis in hypercholesterolemic men. Arterioscler Thromb Vasc Biol: 1997; 17 1 45 50
32. Fowkes F. G., Lowe G. D., Housley E., et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet: 1993; 342 8863 84 86
33. Kanfer A., Kleinknecht D., Broyer M., Josso F. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb Diath Haemorrh: 1970; 24 3 562 571
34. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int: 1985; 28 3 429 439
35. Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost: 1997; 23 3 271 280
36. Kuipers S., Cannegieter S. C., Doggen C. J., Rosendaal F. R. Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. Blood: 2009; 113 9 2064 2069
37. Tsai A. W., Cushman M., Rosamond W. D., et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med: 2002; 113 8 636 642
38. Singhal R., Brimble K. S. Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management. Thromb Res: 2006; 118 3 397 407
39. Orth S. R., Ritz E. The nephrotic syndrome. N Engl J Med: 1998; 338 17 1202 1211
40. Remuzzi G., Marchesi D., Mecca G., de Gaetano G., Silver M. Platelet hypersensitivity in the nephrotic syndrome. Proc Eur Dial Transplant Assoc: 1979; 16 487 494
41. Walter E., Deppermann D., Andrassy K., Koderisch J. Platelet hyperaggregability as a consequence of the nephrotic syndrome. Thromb Res: 1981; 23 6 473 479
42. Sirolli V., Ballone E., Garofalo D., et al. Platelet activation markers in patients with nephrotic syndrome. A comparative study of different platelet function tests. Nephron: 2002; 91 3 424 430
43. Zwaginga J. J., Koomans H. A., Sixma J. J., Rabelink T. J. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest: 1994; 93 1 204 211
44. Soulat T., Loyau S., Baudouin V., et al. Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: an in vitro study using plasma from children with idiopathic nephrotic syndrome. Arterioscler Thromb Vasc Biol: 2000; 20 2 575 584
45. Svenningsen P., Bistrup C., Friis U. G., et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol: 2009; 20 2 299 310
46. Thomson C., Forbes C. D., Prentice C. R., Kennedy A. C. Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Q J Med: 1974; 43 171 399 407
47. Rabelink T. J., Zwaginga J. J., Koomans H. A., Sixma J. J. Thrombosis and hemostasis in renal disease. Kidney Int: 1994; 46 2 287 296
48. Yoshida Y., Shiiki H., Iwano M., et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron: 2001; 88 1 24 29
49. Radhakrishnan J. Venous thromboembolism and membranous nephropathy: so what's new? Clin J Am Soc Nephrol: 2012; 7 1 3 4
50. Dangas G., Mehran R., Harpel P. C., et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol: 1998; 32 7 2035 2042
51. Yoshida Y., Shiiki H., Iwano M., et al. Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome. Nephron: 2001; 88 1 24 29
52. Jennette J. C., Olson J. L., Schwartz M. M., et al. Heptinstall's Pathology of the Kidney. 6th ed. Philadelphia, PA Lippincott Williams & Wilkins: 2007; 126 149
53. Glassock R. J. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol: 2007; 18 8 2221 2225
54. Htike N., Superdock K., Thiruveedi S., Surkis W., Teehan G. Evaluating proteinuria and nephrotic syndrome in patients with venous thromboembolism. Am J Med Sci: 2012; 343 2 124 126
55. Mahmoodi B. K., ten Kate M. K., Waanders F., et al. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation: 2008; 117 2 224 230
56. Ulinski T., Guigonis V., Baudet-Bonneville V., Auber F., Garcette K., Bensman A. Mesenteric thrombosis causing short bowel syndrome in nephrotic syndrome. Pediatr Nephrol: 2003; 18 12 1295 1297
57. Llach F., Papper S., Massry S. G. The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med: 1980; 69 6 819 827
58. Wagoner R. D., Stanson A. W., Holley K. E., Winter C. S. Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance. Kidney Int: 1983; 23 2 368 374
59. Velasquez Forero F., Garcia Prugue N., Ruiz Morales N. Idiopathic nephrotic syndrome of the adult with asymptomatic thrombosis of the renal vein. Am J Nephrol: 1988; 8 6 457 462
60. Cameron J. S. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol Necker Hosp: 1984; 13 75 114
61. Egli F., Elmiger P., Stalder G. Thrombose als Komplikation des nephrotischen Syndroms [Thrombosis as a complication of nephrotic syndrome]. Helv Paediatr Acta: 1973; 30 (Suppl): 20 21
62. Appenzeller S., Zeller C. B., Annichino-Bizzachi J. M., et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clin Neurol Neurosurg: 2005; 107 5 371 378
63. Lionaki S., Derebail V. K., Hogan S. L., et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol: 2012; 7 1 43 51
64. Gigante A., Barbano B., Sardo L., et al. Hypercoagulability and nephrotic syndrome. Curr Vasc Pharmacol: 2012; (e-pub ahead of print)
65. Zhang L. J., Wang Z. J., Zhou C. S., Lu L., Luo S., Lu G. M. Evaluation of pulmonary embolism in pediatric patients with nephrotic syndrome with dual energy CT pulmonary angiography. Acad Radiol: 2012; 19 3 341 348
66. Sullivan M. J. III, Hough D. R., Agodoa L. C. Peripheral arterial thrombosis due to the nephrotic syndrome: the clinical spectrum. South Med J: 1983; 76 8 1011 1016
67. Igarashi M., Roy S. III, Stapleton F. B. Cerebrovascular complications in children with nephrotic syndrome. Pediatr Neurol: 1988; 4 6 362 365
68. Ueda N., Kawaguchi S., Niinomi Y., et al. Effect of corticosteroids on coagulation factors in children with nephrotic syndrome. Pediatr Nephrol: 1987; 1 3 286 289
69. Brater D. C. Mechanism of action of diuretics. 2012, available at http://www.uptodate.com/contents/mechanism-of-action-of-diuretics
70. Kayali F., Najjar R., Aswad F., Matta F., Stein P. D. Venous thromboembolism in patients hospitalized with nephrotic syndrome. Am J Med: 2008; 121 3 226 230
71. Zhang L. J., Wang Z. J., Zhou C. S., Lu L., Luo S., Lu G. M. Evaluation of pulmonary embolism in pediatric patients with nephrotic syndrome with dual energy CT pulmonary angiography. Acad Radiol: 2012; 19 3 341 348
72. Kerlin B. A., Blatt N. B., Fuh B., et al. Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study. J Pediatr: 2009; 155 1 105 110, e1
73. Lefaucheur C., Stengel B., Nochy D., et al. GN-PROGRESS Study Group Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int: 2006; 70 8 1510 1517
74. Beck L. H. Jr. Membranous nephropathy and malignancy. Semin Nephrol: 2010; 30 6 635 644
75. Mismetti P., Quenet S., Levine M., et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest: 2005; 128 4 2203 2210
76. Lai S., Barbano B., Cianci R., et al. Rischio emorragico nell'utilizzo di eparina a basso peso molecolare nel paziente nefropatico. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure]. G Ital Nefrol: 2010; 27 6 649 654
77. Radhakrishnan J. Renal vein thrombosis and hypercoagulable state in nephrotic syndrome. 2012, available at http://www.uptodate.com/contents/renal- vein-thrombosis-and-hypercoagulable-state-in-nephrotic-syndrome
78. Alberts M. J., Bernstein R. A., Naccarelli G. V., Garcia D. A. Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke: 2012; 43 1 271 279
79. Hohnloser S. H., Oldgren J., Yang S., et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation: 2012; 125 5 669 676
80. Poulsen B. K., Grove E. L., Husted S. E. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs: 2012; 72 13 1739 1753
81. Markowitz G. S., Brignol F., Burns E. R., Koenigsberg M., Folkert V. W. Renal vein thrombosis treated with thrombolytic therapy: case report and brief review. Am J Kidney Dis: 1995; 25 5 801 806
82. Paraskevas K. I., Bessias N., Perdikides T. P., Mikhailidis D. P. Statins and venous thromboembolism: a novel effect of statins? Curr Med Res Opin: 2009; 25 7 1807 1809
83. Resh M., Mahmoodi B. K., Navis G. J., Veeger N. J., Lijfering W. M. Statin use in patients with nephrotic syndrome is associated with a lower risk of venous thromboembolism. Thromb Res: 2011; 127 5 395 399
84. Berger J. S., Roncaglioni M. C., Avanzini F., Pangrazzi I., Tognoni G., Brown D. L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA: 2006; 295 3 306 313
85. Glynn R. J., Ridker P. M., Goldhaber S. Z., Buring J. E. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med: 2007; 147 8 525 533
86. Akoglu H., Agbaht K., Piskinpasa S., et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant: 2012; 27 4 1460 1466
87. Tholl U., Anlauf M., Helmchen U. Clopidogrel and membranous nephropathy. Lancet: 1999; 354 9188 1443 1444